EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer

Arvind Kumar iD, Steven Tohmasi iD, Daniel B Eaton, Nahom Seyoum iD, Whitney S Brandt, Theodore S Thomas, Martin W Schoen iD, Nikki E Rossetti, Su-Hsin Chang iD, Yan Yan, Mayank R Patel, Sara Malone und 5 weitere

Cancers · 10.09.2025 · 17 (18) · 2961

DOI: 10.3390/cancers17182961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 10.09.2025. Verfasst von Arvind Kumar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, NCI NIH HHS, Veterans Health Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent clinical trials support adjuvant treatment with novel immunotherapy and targeted therapy agents for selected non-small-cell lung cancer (NSCLC) after resection. The “real-world” implementation of these treatments, however, remains unknown. This study evaluated trends in the uptake of adjuvant chemotherapy, immunotherapy, and targeted therapy for patients with resected NSCLC.

Methods

Patients with resected stage IB-III NSCLC within the Veterans Health Administration (2017−2023) were included. Use of adjuvant chemotherapy, immunotherapy, and/or targeted therapy was evaluated over the study period. Factors associated with adjuvant therapy use were identified using multivariable-adjusted logistic regression.

Results

Of the 1980 patients included, 846 (42.7%) underwent adjuvant therapy. There was a modest but not statistically significant increase in adjuvant therapy use from 37.1% in 2017 to 45.9% in 2023. Use of adjuvant chemotherapy alone declined from 36.6% to 23.5%, while use of adjuvant immunotherapy (0.5% to 21.2%) and targeted therapy (0% to 1.2%) increased. Factors associated with adjuvant therapy use included younger age, fewer comorbidities, and higher tumor stage.

Conclusions

Despite the increased use of adjuvant immunotherapy and targeted therapy for resected stage IB-III NSCLC, overall adjuvant therapy uptake remains low. Further efforts will be necessary to better incorporate these novel treatments into routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

adjuvant therapyimmunotherapymultimodal treatmentnon-small-cell lung cancerresectabletargeted therapy

Autor:innen und Institutionen

  • Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Veterans Affairs St. Louis Health Care System, St. Louis, MO 63110, USA.
  • Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO 63110, USA.
  • Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • School of Public Health, Washington University in St. Louis, St. Louis, MO 63110, USA.

ORCID-Profile: Arvind Kumar, Steven Tohmasi, Nahom Seyoum, Martin W Schoen, Su-Hsin Chang, Molly C Tokaz, Brendan T Heiden

Förderung

  • AstraZeneca
  • NCI NIH HHS
  • Veterans Health Administration
  • HSRD VA
  • National Cancer Institute

Zitieren

APA

Kumar, A., Tohmasi, S., Eaton, D. B., Seyoum, N., Brandt, W. S., Thomas, T. S., Schoen, M. W., Rossetti, N. E., Chang, S. H., Yan, Y., Patel, M. R., Malone, S., Tokaz, M. C., Meyers, B. F., Kozower, B. D., Puri, V., & Heiden, B. T. (2025). Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer. Cancers, 17(18), 2961. https://doi.org/10.3390/cancers17182961

Vancouver

Kumar A, Tohmasi S, Eaton DB, Seyoum N, Brandt WS, Thomas TS, et al. Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer. Cancers. 2025;17(18):2961. doi:10.3390/cancers17182961

BibTeX
@article{Kumar2025,
  author = {Kumar, Arvind and Tohmasi, Steven and Eaton, Daniel B and Seyoum, Nahom and Brandt, Whitney S and Thomas, Theodore S and Schoen, Martin W and Rossetti, Nikki E and Chang, Su-Hsin and Yan, Yan and Patel, Mayank R and Malone, Sara and Tokaz, Molly C and Meyers, Bryan F and Kozower, Benjamin D and Puri, Varun and Heiden, Brendan T},
  title = {Real-World Adoption of Adjuvant Therapies for Resected Stage IB–III Non-Small-Cell Lung Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {2961},
  doi = {10.3390/cancers17182961}
}
Kostenlos starten →